Anna Lauritano

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Exploring the role of β2- and β3-adrenergic receptors in cystic fibrosis.

Exploring the role of β2- and β3-adrenergic receptors in cystic fibrosis.

Journal: Pulmonary pharmacology & therapeutics

Published: May 07, 2025

The effect of medical cannabis on gastrointestinal symptoms in fibromyalgia and disorders of gut-brain interaction: a patient‑centred real‑world observational study.

The effect of medical cannabis on gastrointestinal symptoms in fibromyalgia and disorders of gut-brain interaction: a patient‑centred real‑world observational study.

Journal: Clinical and experimental rheumatology

Published: March 22, 2025

Early biomarkers in the presymptomatic phase of cognitive impairment: changes in the endocannabinoidome and serotonergic pathways in Alzheimer's-prone mice after mTBI.

Early biomarkers in the presymptomatic phase of cognitive impairment: changes in the endocannabinoidome and serotonergic pathways in Alzheimer's-prone mice after mTBI.

Journal: Acta neuropathologica communications

Published: March 13, 2024

Olive oil-derived endocannabinoid-like mediators inhibit palatable food-induced reward and obesity.

Olive oil-derived endocannabinoid-like mediators inhibit palatable food-induced reward and obesity.

Journal: Communications biology

Published: March 09, 2023

Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice.

Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice.

Journal: Journal of neuroinflammation

Published: August 24, 2022

The endocannabinoidome mediator N-oleoylglycine is a novel protective agent against 1-methyl-4-phenyl-pyridinium-induced neurotoxicity.

The endocannabinoidome mediator N-oleoylglycine is a novel protective agent against 1-methyl-4-phenyl-pyridinium-induced neurotoxicity.

Journal: Frontiers in aging neuroscience

Published: April 22, 2022

The Endocannabinoid System: A Bridge between Alzheimer's Disease and Gut Microbiota.

The Endocannabinoid System: A Bridge between Alzheimer's Disease and Gut Microbiota.

Journal: Life (Basel, Switzerland)

Published: August 03, 2021

KCNQ3 is the principal target of retigabine in CA1 and subicular excitatory neurons.

KCNQ3 is the principal target of retigabine in CA1 and subicular excitatory neurons.

Journal: Journal of neurophysiology

Published: March 17, 2021

Protective Effects of N-Oleoylglycine in a Mouse Model of Mild Traumatic Brain Injury.

Protective Effects of N-Oleoylglycine in a Mouse Model of Mild Traumatic Brain Injury.

Journal: ACS chemical neuroscience

Published: February 05, 2020

Synthesis and Pharmacological Characterization of Conformationally Restricted Retigabine Analogues as Novel Neuronal Kv7 Channel Activators.

Synthesis and Pharmacological Characterization of Conformationally Restricted Retigabine Analogues as Novel Neuronal Kv7 Channel Activators.

Journal: Journal of medicinal chemistry

Published: December 10, 2019

A novel homozygous KCNQ3 loss-of-function variant causes non-syndromic intellectual disability and neonatal-onset pharmacodependent epilepsy.

A novel homozygous KCNQ3 loss-of-function variant causes non-syndromic intellectual disability and neonatal-onset pharmacodependent epilepsy.

Journal: Epilepsia open

Published: April 09, 2019

Autism and developmental disability caused by KCNQ3 gain-of-function variants.

Autism and developmental disability caused by KCNQ3 gain-of-function variants.

Journal: Annals of neurology

Published: January 20, 2019

Showing 1-12 of 13

Last Updated: 09/26/2026